Search

C16H12ClFO5, monclinic, P21/c (no. 14), a = 14.7536(6) Å, b = 7.8281(3) Å, c = 14.0501(7) Å, β = 111.174(5)° $111.174(5){}^{\circ}$ , V = 1513.13(12) Å3, Z = 4, R gt(F) = 0.0367, wR ref(F 2) = 0.0865, T = 296(2) K.

Background: Atrial volume index and atrial volume have recently been identified as predictors of atrial fibrillation (AF) recurrence following electrical cardioversion or radiofrequency ablation. However, most studies have reported the relationship between LAVI/LAV and AF recurrence, whereas there is little information on the relationship between RAVI/RAV and AF recurrence. Therefore, we performed a meta-analysis to assess the relationship between the risk of AF recurrence and RAVI/RAV in patients with AF who underwent electrical cardioversion or radiofrequency ablation. Methods: CNKI, Wanfang Database, Pubmed, Embase, Cochrane Library, and Web of Science were searched up to October 01, 2024. A meta-analysis of relative risk data from prospective and retrospective cohort studies that reported on the relationship between the risk of AF recurrence and RAVI/RAV in patients with AF after electrical cardioversion or radiofrequency ablation was performed. Results: The results showed that patients with AF recurrence had a higher mean right atrial volume index (RAVI) compared to patients with no recurrence. After electrical cardioversion or radiofrequency ablation, RAVI can independently predict the recurrence of AF (OR = 1.06, 95%CI (1.02, 1.11)). The average right atrial volume (RAV) of patients with AF recurrence was higher than that of patients without AF recurrence. After electrical cardioversion or radiofrequency ablation, RAV can independently predict the recurrence of AF (OR = 1.02, 95%CI (1.00, 1.05)). Conclusion: Patients with AF recurrence after electrical cardioversion or radio frequency ablation had higher mean RAVI and RAV compared to patients with no recurrence. After electrical cardioversion or radiofrequency ablation in patients with AF, higher levels of RAVI and RAV increase the chance of recurrence of AF. [ABSTRACT FROM AUTHOR]

C11H12O5, orthorhombic, P212121 (no. 19), a = 5.5523(7) Å, b = 12.7610(17) Å, c = 15.374(2) Å, V = 1089.3(2) Å3, Z = 4, R gt(F) = 0.0273, wR ref(F 2) = 0.0787, T = 296(2) K.

C12H14O6, orthorhombic, Pbca (no. 61), a = 18.0207(13) Å, b = 7.6885(5) Å, c = 18.2326(13) Å, V = 2526.2(3) Å3, Z = 8, Rgt(F) = 0.0411, wRref(F2) = 0.1214, T = 296(2) K.

C60H74CdCl6N12O4, triclinic, P1̄ (no. 2), a = 9.1036(18) Å, b = 13.197(3) Å, c = 15.035(3) Å, α = 93.716(2)°, β = 99.904(2)°, γ = 104.928(2)°, V = 1708.0(6) Å3, Z = 2, Rgt(F) = 0.0258, wRref(F2) = 0.0684, T = 296(2) K.

C12H14N4O11, orthorhombic, C2221 (no. 20), a = 4.7425(3) Å, b = 12.5852(9) Å, c = 26.5080(18) Å, V = 1582.14(19) Å3, Z = 4, Rgt(F) = 0.0377, wRref(F2) = 0.1064, T = 296(2) K.

C12H22CdN4O14, triclinic, P1̅ (no. 2), a = 7.188(2) Å, b = 8.895(3) Å, c = 9.771(3) Å, α = 63.148(3)°, β = 76.750(3)°, γ = 66.225(3)°, V = 509.2(3) Å3, Z = 1, Rgt(F) = 0.0253, wRref(F2) = 0.0676, T = 296(2) K.

C16H12ClFO5, monclinic, P21/c (no. 14), a = 14.7536(6) Å, b = 7.8281(3) Å, c = 14.0501(7) Å, β = 111.174 (5) ° , V = 1513.13(12) Å3, Z = 4, Rgt(F) = 0.0367, wRref(F2) = 0.0865, T = 296(2) K. [ABSTRACT FROM AUTHOR]

C12H12O4, monoclinic, P21/c (no. 14), a = 16.071(6) Å, b = 9.424(4) Å, c = 7.640(3) Å, β = 101.861(5)°, V = 1132.4(8) Å3, Z = 4, Rgt(F) = 0.0366, wRref(F2) = 0.1043, T = 296(2) K. [ABSTRACT FROM AUTHOR]

C12H12O4, monoclinic, P21/c (no. 14), a = 16.071(6) Å, b = 9.424(4) Å, c = 7.640(3) Å, β = 101.861(5)°, V = 1132.4(8) Å3, Z = 4, Rgt(F) = 0.0366, wRref(F2) = 0.1043, T = 296(2) K. [ABSTRACT FROM AUTHOR]

C12H14O6, orthorhombic, Pbca (no. 61), a = 18.0207(13) Å, b = 7.6885(5) Å, c = 18.2326(13) Å, V = 2526.2(3) Å3, Z = 8, Rgt(F) = 0.0411, wRref(F2) = 0.1214, T = 296(2) K. [ABSTRACT FROM AUTHOR]

C60H74CdCl6N12O4, triclinic, P1̄ (no. 2), a = 9.1036(18) Å, b = 13.197(3) Å, c = 15.035(3) Å, α = 93.716(2)°, β = 99.904(2)°, γ = 104.928(2)°, V = 1708.0(6) Å3, Z = 2, Rgt(F) = 0.0258, wRref(F2) = 0.0684, T = 296(2) K. [ABSTRACT FROM AUTHOR]

[C14H14F3N5O6S], monoclinic, P21/c (No. 14), a = 12.512(4) Å, b = 12.572(4) Å, c = 12.511(4) Å, β = 114.39(1)°, V = 1792.5(11) ų, Z = 4, Rgt(F) = 0.0366, wRref(F²) = 0.0849, T = 296(2) K. [ABSTRACT FROM AUTHOR]

C12H14N4O11, orthorhombic, C2221 (no. 20), a = 4.7425(3) Å, b = 12.5852(9) Å, c = 26.5080(18) Å, V = 1582.14(19) Å3, Z = 4, Rgt(F) = 0.0377, wRref(F2) = 0.1064, T = 296(2) K. [ABSTRACT FROM AUTHOR]

C12H22CdN4O14, triclinic, P1̅ (no. 2), a = 7.188(2) Å, b = 8.895(3) Å, c = 9.771(3) Å, α = 63.148(3)°, β = 76.750(3)°, γ = 66.225(3)°, V = 509.2(3) Å3, Z = 1, Rgt (F) = 0.0253, wRref (F2) = 0.0676, T = 296(2) K. [ABSTRACT FROM AUTHOR]

In the crystal structure of the title compound, [CoCl(2)(C(15)H(17)Cl(2)N(3)O)(4)], the Co(II) cation lies on an inversion center and has a slightly distorted octa-hedral coordination geometry. The equatorial positions are occupied by four N atoms from four diniconazole [systematic name: (E)-(RS)-1-(2,4-dichloro-phen-yl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol] ligands. The axial sites are occupied by two Cl(-) anions. In the two independent organic ligands, the triazole ring is oriented at dihedral angles of 18.28 (14) and 32.15 (14)° with respect to the dichloro-phenyl ring. Inter-molecular O-H⋯Cl hydrogen bonds consolidate the crystal packing.

In the title compound, [NiCl(2)(C(15)H(17)Cl(2)N(3)O)(4)], the Ni atom lies on an inversion center and has an axially extended trans-NiCl(2)N(4) octa-hedral geometry arising from its coordination by four diniconazole [systematic name: (E)-(RS)-1-(2,4-dichloro-phen-yl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol] ligands and two chloride ions. In the crystal, O-H⋯Cl hydrogen bonds link the mol-ecules into [100] chains.